![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/29/2889688/0/en/Atea-Pharmaceuticals-to-Present-at-the-Jefferies-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/22/2886350/0/en/Atea-Pharmaceuticals-Presents-New-Data-Showcasing-Potential-Best-in-Class-Combination-Profile-of-Bemnifosbuvir-and-Ruzasvir-for-Treatment-of-Hepatitis-C-Virus-at-EASL-Congress-2024.html
https://www.globenewswire.com/news-release/2024/05/14/2881874/0/en/Atea-Pharmaceuticals-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/05/07/2876546/0/en/Atea-Pharmaceuticals-to-Host-First-Quarter-2024-Financial-Results-Conference-Call-on-May-14-2024.html
https://www.globenewswire.com/news-release/2024/04/29/2871068/0/en/Atea-Announces-Presentation-of-Data-Highlighting-Favorable-Safety-Profile-of-Bemnifosbuvir-at-ESCMID-Global-2024.html
https://www.globenewswire.com/news-release/2024/03/27/2853010/0/en/Atea-Pharmaceuticals-Completes-Patient-Enrollment-in-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Oral-Antiviral-Bemnifosbuvir-for-COVID-19-in-High-Risk-Patients.html
https://www.globenewswire.com//news-release/2024/02/28/2837414/0/en/Atea-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com//news-release/2024/02/21/2832614/0/en/Atea-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2023-Financial-Results-Conference-Call-on-February-28-2024.html
https://www.globenewswire.com//news-release/2024/01/08/2805848/0/en/Atea-Pharmaceuticals-Announces-Positive-Initial-Data-from-Phase-2-Study-for-Hepatitis-C-Virus-HCV-and-Significant-Enrollment-Milestone-for-Phase-3-SUNRISE-3-Trial-for-COVID-19.html
https://www.globenewswire.com//news-release/2024/01/03/2803148/0/en/Atea-Pharmaceuticals-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html